SUBSCRIBE
SUBSCRIBE

Krystal Biotech

NEWS
Drug Development
Krystal Biotech Announces Positive Interim Results from Placebo-Controlled Phase 1/2 Clinical Trial of KB103
KB103 is Krystal’s first “off-the-shelf”, topical, gene therapy candidate to treat patients suffering from Dystrophic Epidermolysis Bullosa.
October 19, 2018
 · 
9 min read
3 Biotechs That Could be Taken Out This Quarter
Deals
Gene Therapy Firm Krystal Biotech Files for $35 Million IPO
August 22, 2017
 · 
2 min read
Load More
JOBS
IN THE PRESS
Press Releases
Krystal Biotech to Present at TD Cowen 46th Annual Health Care Conference
February 24, 2026
 · 
1 min read
Press Releases
Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results
February 17, 2026
 · 
18 min read
Press Releases
Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
February 10, 2026
 · 
1 min read
Press Releases
Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
February 9, 2026
 · 
2 min read
Press Releases
Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
January 12, 2026
 · 
7 min read
Press Releases
Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis
January 9, 2026
 · 
9 min read
Press Releases
Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis
January 8, 2026
 · 
1 min read
Press Releases
Krystal Biotech to Present at 44th Annual J.P. Morgan Healthcare Conference
January 5, 2026
 · 
1 min read
Press Releases
Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference
November 27, 2025
 · 
1 min read
Press Releases
Krystal Biotech Announces Third Quarter 2025 Financial and Operating Results
November 4, 2025
 · 
20 min read
Load More